"Continuing Application Data

This application is a continuation-in-part of U.S. Application Serial No. 09/325,557, filed June 4, 1999, now abandoned, which, in turn, claims the benefit of U.S. Provisional Application Serial No. 60/103,866, filed October 12, 1998."

In the Claims:

Please amend Claims 52, 56, 58, 59, 61, 65, and 67 to read as follows:

52. (Amended) A compound represented by Formula I:

 $(L)_p(X)_q$

I

where

each L is a ligand that may be the same or different at each occurrence;

X is a linker that may be the same or different at each occurrence;

p is an integer of from 2 to 10;

q is an integer of from 1 to 20;

and wherein L is selected from the group consisting of formula (i), formula (ii),

formula (iii), formula (iv), formula (v), and formula (vi):

Sylvania Sylvania

Response to Office Action Application No. 09/456,429 Attorney's Docket No. 032367-451 (AMI-015-RP1)

and wherein each linker, X, is represented by the following formula:

in which:

m is an integer from 0 to 20;


X' at each separate occurrence is -O-, -S-, S(O)-, -S(O)2-, -NR-, -NRR', -C(O)-, C(O)O-, -C(O)NH-, -C(S)O-, -C(S)NH- or a covalent bond, where R and R' at each separate occurrence are as defined below for R' and R";

Z is at each separate occurrence selected from alkylene, substituted alkylene, alkylalkoxy, cycloalkylene, substituted cycloalkylene, alkenylene, substituted alkenylene, alkynylene, substituted alkynylene, cycloalkenylene, substituted cycloalkenylene, arylene, substituted arylene, heteroarylene, heterocyclene, substituted heterocyclene, crown compounds or a covalent bond;

Y' and Y" at each separate occurrence are selected from -S-S-, a covalent bond or a structure selected from the following group:

$$\begin{array}{c|c}
O \\
N \\
R'
\end{array}$$

Carr



in which:

n is 0, 1 or 2; and

R' and R" at each separate occurrence are selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkynyl, aryl, heteroaryl or heterocyclic;

and further wherein each of said ligands comprises a ligand domain capable of binding to a Ca⁺⁺ channel.

- 56. (Amended) The compound according to Claim 52, wherein p is 2 and q is 1.
- 58. (Amended) The compound according to Claim 56 wherein L is a ligand of formula (ii) or offormula (vi).
- 59. (Amended) The compound according to Claim 56 wherein L is a ligand of formula (iv) or of formula (vi).
- 61. Amended) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of one or more compounds represented by Formula I:

Cin.

 \mathbb{R}^5

where

each L is a ligand that may be the same or different at each occurrence;

X is a linker that may be the same or different at each occurrence;

p is an integer of from 2 to 10;

q is an integer of from 1 to 20;

and wherein L is selected from the group consisting of formula (i), formula (ii),



Response to Office Action Application No. 09/456,429 Attorney's Docket No. 032367-451 (AMI-015-RP1) Page 7

and wherein each linker, X, is represented by the following formula:

$$-X'-Z-(Y'-Z)_m-Y''-Z-X'-$$

in which:

m is an integer from 0 to 20;

X' at each separate occurrence is -O-, -S-, -S(O)-, -S(O)2-, -NR-, -NRR', -C(O)-, -C(O)O-, -C(O)NH-, -C(S)-, -C(S)O-, -C(S)NH- or a covalent bond, where R and R at each separate occurrence are as defined below for R' and R";

Z is at each separate occurrence selected from alkylene, substituted alkylene, alkylalkoxy, cycloalkylene, substituted cycloalkylene, alkenylene, substituted alkynylene, cycloalkenylene, substituted cycloalkenylene, arylene, substituted arylene, heteroarylene, heterocyclene, substituted heterocyclene, crown compounds or a covalent bond;

Y' and Y" at each separate occurrence are selected from -S-S-, a covalent bond or a structure selected from the following group:

$$\begin{array}{c|cccc}
O & & & & & & & & \\
N & & & & & & & \\
R' & & & & & & \\
R' & & & & & & \\
R' & & & & \\
R' & & & & & \\
R' & & \\
R' & & & \\
R' & & \\
R' & & & \\
R' & & \\
R' & & \\
R' & & \\
R' & & \\
R'$$

(ren.

Response to Office Action Application No. 09/456,429 Attorney's Docket No. <u>032367-451 (AMI-015-RP1)</u> Page 9

N O O

 $-S(O)_n$ -CR'R"-

-S(O)_n-NR'-

BS Con.

in which:

n is 0, 1 or 2, and

R' and R" at each separate occurrence are selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, heteroaryl or heterocyclic;

and further wherein each of said ligands comprises a ligand domain capable of binding to a Ca⁺⁺ channel.

 $\leq 65.$

. (Amended) The composition according to Claim 61, wherein p is 2 and q is 1.

12

67. (Amended) The composition according to Claim 65 wherein L is a ligand of formula (ii) or of formula (vi).

Please cancel Claims 55, 57, 64, and 66 without prejudice or disclaimer.

Please add new Claims 69 – 73.

69. (New) The composition according to Claim 65 wherein L is a ligand of formula (iv) or of formula (vi).

38

70. (New) The compound according to Claim 56 wherein L is a ligand of formula (i).

71. (New) The compound according to Claim 56 wherein one L is a ligand of formula (i) and one L is a ligand of formula (v).